Precision for Medicine Executive and Leadership Team

Eugene Vodovoz, the Chief Financial Officer at Precision for Medicine, directs all fiscal planning and capital allocation strategies. Managing the financial health of the organization, the Chief Financial Officer oversees budgeting, forecasting, and long-term investment initiatives to ensure sustainable growth. This leadership role involves maintaining rigorous compliance standards while supporting the infrastructure needs of life science clients. By optimizing resource distribution, Eugene Vodovoz directly impacts the ability of the company to scale development services across North American and European markets. The Chief Financial Officer collaborates with the executive board to align financial performance with the broader mission of reducing costs for biotechnology partners. Through precise fiscal oversight, Vodovoz secures the necessary capital to fuel innovation and maintain a competitive edge in the life science services sector, ultimately driving the financial stability required for complex clinical development projects.

Chad Clark, the President and Chief Operating Officer, Precision Medicine Group at Precision for Medicine, architects the operational framework for development and commercialization services. Overseeing the integration of cross-functional teams, the President and Chief Operating Officer, Precision Medicine Group ensures that life science companies receive seamless support throughout the drug approval process. This leadership role involves streamlining internal workflows to maximize efficiency and reduce time-to-market for critical therapies. By managing complex service delivery models, Chad Clark directly impacts the operational success of the organization. The President and Chief Operating Officer, Precision Medicine Group coordinates with other C-suite leaders to refine the platform infrastructure, ensuring that global operations remain agile and responsive to industry shifts. Through strategic oversight of service execution, Clark maintains high standards of quality and performance, ultimately enabling the company to deliver superior value to clients navigating the challenging landscape of modern medicine.

Daisy DeWeese-Gatt, the President, Clinical Solutions at Precision for Medicine, directs the strategy and execution of clinical development services. Overseeing the design and implementation of complex trials, the President, Clinical Solutions ensures that life science companies achieve regulatory milestones with maximum efficiency. This leadership role involves managing clinical operations teams and integrating advanced data analytics to support the drug approval process. By optimizing trial protocols, Daisy DeWeese-Gatt directly impacts the speed and cost-effectiveness of client projects. The President, Clinical Solutions collaborates with the broader executive team to refine the service platform, ensuring that clinical outcomes align with commercialization goals. Through rigorous oversight of trial management and site performance, DeWeese-Gatt maintains the highest standards of scientific integrity, ultimately enabling the company to provide the infrastructure necessary for bringing life-saving therapies to market across global healthcare systems.

Sofia Baig, the President, Precision for Medicine at Precision for Medicine, architects the overarching strategic vision for the organization. Overseeing the alignment of development and commercialization services, the President, Precision for Medicine ensures that the company platform consistently meets the evolving needs of life science partners. This leadership role involves guiding the executive team to foster innovation and maintain operational excellence across all service lines. By driving the long-term growth strategy, Sofia Baig directly impacts the market position of the firm as a leader in life science infrastructure. The President, Precision for Medicine collaborates with the Board to ensure that corporate objectives support the mission of reducing costs and speeding approval for biotechnology clients. Through decisive leadership and a focus on scalable solutions, Baig secures the future of the organization, ensuring that the company remains at the forefront of the global effort to optimize medical development and commercial success.

James Cheong, the Senior VP (Asia Pacific) at Precision for Medicine, drives all business development and operational initiatives across the Asia Pacific region. Overseeing market entry strategies, the Senior VP (Asia Pacific) ensures that the company platform effectively supports local life science companies in speeding approval and optimizing commercialization. This leadership role involves building strategic partnerships and navigating regional regulatory environments to expand the footprint of the organization. By tailoring service delivery to meet the unique needs of Asian markets, James Cheong directly impacts the global growth trajectory of the firm. The Senior VP (Asia Pacific) collaborates with international teams to align regional activities with the overarching corporate mission of reducing costs for biotechnology partners. Through consistent market analysis and operational excellence, Cheong secures a strong competitive position, ensuring that the company remains a preferred partner for life science innovation throughout the diverse and rapidly evolving Asia Pacific landscape.